Navigation Links
Bioness Inc. Receives FDA Clearance and CE Mark for Its NESS H200 Wireless System for Hand Paralysis as a Result of Stroke and Other Central Nervous System Disorders

VALENCIA, Calif., Oct. 4, 2011 /PRNewswire/ -- Bioness Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark Approval by the European Union for its NESS H200® Wireless Hand Rehabilitation System. This new wireless system allows patients to better integrate the NESS H200 into daily life, increasing therapy time which may lead to increased patient compliance and better outcomes.

The NESS H200 Wireless is an advanced hand rehabilitation system designed to use mild Functional Electrical Stimulation (FES) to improve hand function and promote motor recovery in patients who have lost function of their upper extremity following injury to the central nervous system such as stroke, traumatic brain injury or spinal cord injury. The device is intended to provide certain individuals with hand paralysis the ability to grasp and release objects while performing ordinary and essential activities of daily living.

"It is well known in rehabilitation that frequency of therapy and training has a direct impact on outcomes. Simply put, the more patients are able to be active and integrate therapy into their day to day lives, the better their outcomes," said Todd Cushman, Senior Vice-President of Global Business Development and Marketing for Bioness. "Our NESS H200 wireless device provides millions of stroke survivors that suffer hand paralysis a way to seamlessly and practically incorporate hand and arm activity into everyday life, allowing for increased therapy time with improved outcomes."

The device consists of three components: a wireless, lightweight and comfortable functional stimulation support (orthosis); a small handheld control unit that communicates wirelessly with the system; and a clinician's programmer that allows for easy programming and patient activity tracking. Designed for use in both the rehabilitation setting and the home, the NESS H200 Wireless may reduce muscle spasm, prevent muscle atrophy, reeducate muscles, increase local blood circulation and may improve hand activity or range of motion.

The company anticipates the NESS H200 Wireless will become commercially available to neurorehabilitation hospitals and centers in the U.S. and Europe, and to consumers for home use, later this year.

About Bioness Inc.

Bioness provides neuromodulation technologies that help improve lives and restore function for those living with neurological deficits and peripheral pain. The Company markets innovative neuromodulation products that help individuals with central nervous system disorders such as stroke, multiple sclerosis, spinal cord injury and traumatic brain injury regain movement in affected limbs. The NESS L300® Foot Drop System and NESS H200® Hand Rehabilitation System, and NESS L300® Plus System, cleared for use by the Food and Drug Administration, are designed to help patients achieve new levels of physical independence and productivity. Individual results vary. Consult with a qualified physician to find out if these products are right for you. Additional information about Bioness can be found at

NESS®, NESS L300®, NESS L300® Plus, NESS H200®, NESS H200® Wireless, Bioness® are trademarks of Bioness Inc | | Rx Only

Media Contact:

Wendy Ryan/Courtney Conery
Schwartz MSL

SOURCE Bioness Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bioness Inc. Receives FDA Clearance of Its NESS L300 Plus System
2. Bioness Inc Announces Availability of L300 Plus System
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
(Date:12/1/2015)... och UPPSALA, Sverige, December 1, 2015 ... International Breast Cancer Study Group (IBCSG, ... Bryssel) att ingå i en klinisk studie av ... --> --> Studien, med namn ... behandlas med anti-hormonella läkemedel i kombination med palbociclib, ...
(Date:11/30/2015)... Minn. and BASEL, Switzerland ... Laboratories, Inc. (Upsher-Smith), through its wholly-owned UK subsidiary ... further development of a novel, oral small molecule inhibitor ... that may be effective in the treatment of inflammatory ... clinical development. --> --> ...
(Date:11/30/2015)... 1, 2015 Express Scripts (NASDAQ: ESRX ) ... IMMY ) to drive access to a low-cost alternative to ... toxoplasmosis that has been recently priced out of reach for ... systems. --> --> Imprimis ... (a form of folic acid) for $1 per capsule for people ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Third Molar SEO ... it has officially launched a sleek, mobile-ready and user-centric redesigned website. , Vivek ... website clearly outlines the benefits that its SEO services provide to dentists and ...
(Date:11/30/2015)... ... 2015 , ... Trevor and Taylor Crabb have unveiled an exciting new ... represent the United States. This hybrid crowdfunding campaign is designed to provide ... in addition to offering corporate sponsors with some great marketing deliverables with the brothers ...
(Date:11/30/2015)... , ... December 01, 2015 , ... ... Christina Colon as a 2015-2016 inductee into its VIP Woman of the ... NAPW is the nation’s leading networking organization exclusively for professional women, boasting 850,000 ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National Association ... inductee into its VIP Woman of the Year Circle. She is recognized with ... organization exclusively for professional women, boasting 850,000 members and over 200 operating Local ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is ... insurance plans on . The multi-carrier insurance exchange platform offers individual ... allowing consumers to compare, quote and match plans to meet their needs. ...
Breaking Medicine News(10 mins):